Citations

Clear

3138 citation(s) found for "Smith, AM".

RNAi screening identifies a mechanosensitive ROCK-JAK2-STAT3 network central to myofibroblast activation
Oh, Raymond , Haak, Andrew J. , Smith, Karry M. J. , Ligresti, Giovanni , Choi, Kyoung Moo , Xie, Tiao , Wang, Shaohua , Walters, P. , Freeman, Michelle, Manlove, L., Chu, Vivian, Roden, Anja C. , Schymeinsky, Jürgen , Prakash, Y. S. , Vassallo, Robert , Tschumperlin, Daniel J. , Oh, Raymond S , Walters, Paula R, Freeman, Michelle R, Manlove, Logan J, Chu, Vivian M, Tschumperlin, Daniel J , Prakash, Y S , Vassallo, Robert , Thompson, Michael A. , Feghali‐Bostwick, Carol A. , Pabelick, Christina M.

Mayo Clinic

Journal of Cell Science | May 15, 2018 | Volume: 131 | Issue: 10 | Pages: No page available

10.1242/jcs.209932 | PMID 29678906 Get It

ABSTRACT Myofibroblasts play key roles in wound healing and pathological fibrosis. Here, we used an RNAi screen to characterize myofibroblast regulatory genes, using a high-content imaging approach to quantify α-smooth muscle actin stress fibers in cultured human fibroblasts. Screen hits were validated on physiological compliance hydrogels, and selected hits tested in primary fibroblasts from patients with idiopathic pulmonary fibrosis. Our RNAi screen led to the identification of STAT3 as an essential mediator of myofibroblast activation and function. Strikingly, we found that STAT3 phosphorylation, while responsive to exogenous ligands on both soft and stiff matrices, is innately active on a stiff matrix in a ligand/receptor-independent, but ROCK- and JAK2-dependent fashion. These results demonstrate how a cytokine-inducible signal can become persistently activated by pathological matrix stiffening. Consistent with a pivotal role for this pathway in driving persistent fibrosis, a STAT3 inhibitor attenuated murine pulmonary fibrosis when administered in a therapeutic fashion after bleomycin injury. Our results identify novel genes essential for the myofibroblast phenotype, and point to STAT3 as an important target in pulmonary fibrosis and other fibrotic diseases.
Glycemic Control and Bone Turnover in Older Mexican Americans with Type 2 Diabetes
Rianon, Nahid , Smith, Scott M. , Lee, MinJae , Pervin, Hannah, Musgrave, Paul W., Watt, Gordon P. , Nader, Shahla, McCormick, Joseph B. , Fisher‐Hoch, Susan P. , Rianon, Nahid J , Khosla, Sundeep , Ambrose, Catherine Glauber

Mayo Clinic

Journal of Osteoporosis | May 13, 2018 | Volume: 2018 | Issue: No issue available | Pages: 1-7

10.1155/2018/7153021 | PMID 29862008 Get It

Altered bone quality, caused by underlying metabolic changes of type 2 diabetes (T2D), has been hypothesized to cause altered bone strength and turnover leading to increased fracture risk in T2D patients. Current understanding about changes in bone turnover markers in T2D patients is mainly based on studies focused on Caucasian men and women. However, Hispanic populations have the highest prevalence of both T2D and osteoporosis in the US. We investigated associations of glycemic control (in terms of glycated hemoglobin [HbA1c]) and bone turnover rate in 69 older (≥50 years) Mexican American Cameron County Hispanic Cohort (CCHC) participants with T2D. Multivariable analyses were conducted to assess the associations between HbA1c (%), serum osteocalcin (OC), and serum sclerostin. In agreement with published reports from other racial/ethnic populations, our study found that lower bone turnover (indicated by lower serum OC) occurred in Mexican American men with T2D who had poorer glycemic control. For the women in our study, we found no significant association between glycemic control and OC. In contrast, HbA1c was positively associated with sclerostin for women, with near significance (p=0.07), while no association was found in men. We recommend screening Mexican American individuals with T2D, specifically those with poor glycemic control, for bone loss and fracture risk.
Functional Invalidation of Putative Sudden Infant Death Syndrome–Associated Variants in the KCNH2 -Encoded Kv11.1 Channel
Tester, David J. , Hall, Allison R., Burgess, Don E. , Hsu, Chun‐Chun , Elayi, Samy Claude, Anderson, Corey L. , January, Craig T., Luo, Jonathan Z. , Hartzel, Dustin N. , Murray, Michael F. , Ackerman, Michael J. , Delisle, Brian P. , Smith, Jennifer L. , Mirshahi, Uyenlinh L. , Mirshahi, Tooraj

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | May 11, 2018 | Volume: 11 | Issue: 5 | Pages: No page available

10.1161/circep.117.005859 | PMID 29752375 Get It

Background: Heterologous functional validation studies of putative long-QT syndrome subtype 2–associated variants clarify their pathological potential and identify disease mechanism(s) for most variants studied. The purpose of this study is to clarify the pathological potential for rare nonsynonymous KCNH2 variants seemingly associated with sudden infant death syndrome. Methods: Genetic testing of 292 sudden infant death syndrome cases identified 9 KCNH2 variants: E90K, R181Q, A190T, G294V, R791W, P967L, R1005W, R1047L, and Q1068R. Previous studies show R181Q-, P967L-, and R1047L-Kv11.1 channels function similar to wild-type Kv11.1 channels, whereas Q1068R-Kv11.1 channels accelerate inactivation gating. We studied the biochemical and biophysical properties for E90K-, G294V-, R791W-, and R1005W-Kv11.1 channels expressed in human embryonic kidney 293 cells; examined the electronic health records of patients who were genotype positive for the sudden infant death syndrome–linked KCNH2 variants; and simulated their functional impact using computational models of the human ventricular action potential. RESULTS: Western blot and voltage-clamping analyses of cells expressing E90K-, G294V-, R791W-, and R1005W-Kv11.1 channels demonstrated these variants express and generate peak Kv11.1 current levels similar to cells expressing wild-type-Kv11.1 channels, but R791W- and R1005W-Kv11.1 channels accelerated deactivation and activation gating, respectively. Electronic health records of patients with the sudden infant death syndrome–linked KCNH2 variants showed that the patients had median heart rate–corrected QT intervals <480 ms and none had been diagnosed with long-QT syndrome or experienced cardiac arrest. Simulating the impact of dysfunctional gating variants predicted that they have little impact on ventricular action potential duration. Conclusions: We conclude that these rare Kv11.1 missense variants are not long-QT syndrome subtype 2–causative variants and therefore do not represent the pathogenic substrate for sudden infant death syndrome in the variant-positive infants.
Comparison of the QuantiFERON-TB Gold Plus and QuantiFERON-TB Gold In-Tube Interferon Gamma Release Assays in Patients at Risk for Tuberculosis and in Health Care Workers
Theel, Elitza S. , Hilgart, Heather, Breen‐Lyles, Margaret K., McCoy, Kevin , Flury, Rhiannon, Breeher, Laura E. , Sia, Irene G. , Whitaker, Jennifer A. , Clain, Jeremy M., Aksamit, Timothy R. , Escalante, Patricio , Breen-Lyles, Margaret, Clain, Jeremy, Breeher, Laura , Wilson, John , Sia, Irene G

Mayo Clinic

Journal of Clinical Microbiology | May 10, 2018 | Volume: 56 | Issue: 7 | Pages: No page available

10.1128/jcm.00614-18 | PMID 29743310 Get It

ABSTRACT The QuantiFERON-TB Gold Plus (QFT-Plus; Qiagen, Germantown, MD) interferon gamma release assay (IGRA) received FDA clearance in 2017 and will replace the prior version of the assay, the QFT-Gold In-Tube (QFT-GIT). Here, we compared performances of the QFT-Plus assay and the QFT-GIT version in a diverse patient population, including patients undergoing evaluation for or follow-up of latent tuberculosis infection (LTBI; n = 39) or active TB infection ( n = 3), and in health care workers (HCWs; n = 119) at Mayo Clinic (Rochester, MN). Compared to the QFT-GIT, the QFT-Plus assay showed 91.2% (31/34) positive, 98.4% (124/126) negative, and 96.6% (156/161) overall qualitative agreement among the 161 enrolled subjects, with a Cohen's kappa value of 0.91 (excellent interrater agreement). Among the 28 patients diagnosed with LTBI at the time of enrollment, the QFT-GIT and QFT-Plus assays agreed in 24 (85.7%) patients; in all four discordant patients, the positivity of the QFT-GIT or QFT-Plus IGRA was associated with low-level interferon gamma (IFN-γ) reactivity, ranging from 0.36 IU/ml to 0.66 IU/ml. Additionally, we document a high degree of correlation between IFN-γ levels in the QFT-GIT TB antigen tube and each of the two QFT-Plus TB antigen tubes, as well as between the QFT-Plus TB1 and TB2 tubes (Pearson's correlation coefficients [ R ] > 0.95). Overall, we show comparable results between the QFT-GIT and QFT-Plus assays in our study population composed of subjects presenting with a diverse spectrum of TB infections. Our findings suggest that the necessary transition to the QFT-Plus assay will be associated with a minimal difference in assay performance characteristics.
HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes
Wang, Sophia , Carrington, Mary , Berndt, Sonja I. , Bracci, Paige M. , Smedby, Karin E. , Hjalgrim, Henrik , Vijai, Joseph , Morton, Lindsay M. , Vermeulen, Roel , Paltiel, Ora , Vajdic, Claire M. , Linet, Martha S. , Nieters, Alexandra , Sanjosé, Sílvia de, Brown, Elizabeth E. , Turner, Jennifer , Spinelli, John J., Zheng, Tongzhang, Birmann, Brenda M. , Flowers, Christopher R. , Becker, Nikolaus, Holly, Elizabeth A., Kane, Eleanor , Weisenburger, Dennis D. , Cocco, Pierluigi, Weinstein, Stephanie J. , Diver, W. Ryan , Lax, S. , Travis, Ruth C., Kaaks, Rudolph, Ríboli, Elio , Benavente, Yolanda , Brennan, Paul, McKay, James , Delfau‐Larue, Marie‐Hélène , Link, Brian K. , Magnani, Corrado , Latte, Giancarlo, Doo, Nicole Wong , Offit, Kenneth , Musinsky, Jacob, Arslan, Alan A. , Purdue, Mark P. , Adami, Hans‐Olov , Melbye, Mads , Glimelius, Bengt , Conde, Lucía , Camp, Nicola J. , Glenn, Martha, Curtin, Karen , Clavel, Jacqueline , Monnereau, Alain, Cox, David G. , Ghesquières, Hervé , Salles, Gilles , Bofetta, Paulo, Foretová, Lenka , Staines, Anthony , Davis, S. Scott , Severson, Richard K., Lan, Qing , Brooks‐Wilson, Angela , Smith, Martyn T. , Roman, Eve , Kricker, Anne , Zhang, Yawei , Kraft, Peter , Rothman, Nathaniel , Hartge, Patricia, Skibola, Christine F., Cocco, Pierluigi , Travis, Ruth C. , Monnereau, Alain , Turner, Jennifer , Weinstein, Stephanie J , Link, Brian K , Joseph, Vijai , Cocco, Pierluigi , Brooks-Wilson, Angela R , Vajdic, Claire M , Kane, Eleanor , Arslan, Alan A , Travis, Ruth C , Kraft, Peter , Morton, Lindsay M , Salles, Gilles A , Wang, Sophia S , Birmann, Brenda M , Roman, Eve , Clavel, Jacqueline , Riboli, Elio , Slager, Susan L. , Voutsinas, Jenna M. , Cerhan, James R. , Cozen, Wendy , Maynadié, Marc , Albanes, Demetrius , Teras, Lauren R. , Ennas, Maria Grazia , Feldman, Andrew L. , Giles, Graham G. , Southey, Melissa C. , Milne, Roger L. , Chanock, Stephen Jacob , Doo, Nicole Wong

Mayo Clinic

Cancer Research | May 7, 2018 | Volume: 78 | Issue: 14 | Pages: 4086-4096

10.1158/0008-5472.can-17-2900 | PMID 29735552 Get It

Abstract A growing number of loci within the human leukocyte antigen (HLA) region have been implicated in non-Hodgkin lymphoma (NHL) etiology. Here, we test a complementary hypothesis of “heterozygote advantage” regarding the role of HLA and NHL, whereby HLA diversity is beneficial and homozygous HLA loci are associated with increased disease risk. HLA alleles at class I and II loci were imputed from genome-wide association studies (GWAS) using SNP2HLA for 3,617 diffuse large B-cell lymphomas (DLBCL), 2,686 follicular lymphomas (FL), 2,878 chronic lymphocytic leukemia/small lymphocytic lymphomas (CLL/SLL), 741 marginal zone lymphomas (MZL), and 8,753 controls of European descent. Both DLBCL and MZL risk were elevated with homozygosity at class I HLA-B and -C loci (OR DLBCL = 1.31, 95% CI = 1.06–1.60; OR MZL = 1.45, 95% CI = 1.12–1.89) and class II HLA-DRB1 locus (OR DLBCL = 2.10, 95% CI = 1.24–3.55; OR MZL = 2.10, 95% CI = 0.99–4.45). Increased FL risk was observed with the overall increase in number of homozygous HLA class II loci (P trend &lt; 0.0001, FDR = 0.0005). These results support a role for HLA zygosity in NHL etiology and suggests that distinct immune pathways may underly the etiology of the different NHL subtypes. Significance: HLA gene diversity reduces risk for non-Hodgkin lymphoma. Cancer Res; 78(14); 4086–96. ©2018 AACR.
Bacteriostasis and Hemostasis by the Use of Fibrin Foam and Penicillin
Baker, George S., Smith, Clyn, Baker, George S.

Mayo Clinic

Military Medicine | May 7, 2018 | Volume: 101 | Issue: 3 | Pages: 208-211

10.1093/milmed/101.3.208 Get It

Oxybutynin for Hot Flashes Due to Androgen Deprivation in Men
Loprinzi, Charles L. , Deville, Curtiland , Deville, Curtiland , Smith, Thomas J.

Mayo Clinic

New England Journal of Medicine | May 2, 2018 | Volume: 378 | Issue: 18 | Pages: 1745-1746

10.1056/nejmc1801992 | PMID 29719180 Get It

Oversight and Ethical Regulation of Conflicts of Interest in Neurosurgery in the United States
DiRisio, Aislyn C. , Muskens, Ivo S. , Coté, David J. , Babu, Maya , Gormley, William B. , Smith, Timothy R. , Moojen, Wouter A. , Broekman, Marike L. D.

Mayo Clinic

Neurosurgery | May 2, 2018 | Volume: 84 | Issue: 2 | Pages: 305-312

10.1093/neuros/nyy227 | PMID 29850841 Get It

Abstract BACKGROUND Developmental incentives are fundamental to surgical progress, yet financial and professional incentives inherently create conflicts of interest (COI). Understanding how to manage COI held by neurosurgeons, industry, hospitals, and journal editors, without thwarting progress and innovation is critical. OBJECTIVE To present an overview of COI associated with innovation in neurosurgery, and review ways to manage these in an ethically sound manner. METHODS A review of the literature was performed to assess conflicts of interest that affect neurosurgical innovation, and review ways to manage COI of various parties while adhering to ethical standards. RESULTS COI are inherent to collaboration and innovation, and are therefore an unavoidable component of neurosurgery. The lack of a clear distinction between clinical practice and innovation, ability to use devices off-label, and unstandardized disclosure requirements create inconsistencies in the way that conflicts of interest are handled. Additionally, lack of requirements to compare innovation to the standard of care and inherent bias that affects study design and interpretation can have profound effects on the medical literature. Conflicts of interest can have both direct and downstream effects on neurosurgical practice, and it is possible to manage them while improving the quality of research and innovation. CONCLUSION Conflicts of interest are inherent to surgical innovation, and can be handled in an ethically sound manner. Neurosurgeons, device companies, hospitals, and medical journals can take steps to proactively confront bias and ensure patient autonomy and safety. These steps can preserve public trust and ultimately improve evidence-based neurosurgical practice.
The Impact of Pazopanib on the Cardiovascular System
Justice, Cody N. , Derbala, Mohamed H. , Baich, Tesla M., Kempton, Amber, Guo, Aaron , Ho, Thai H. , Smith, Sakima A. , Ho, Thai

Mayo Clinic

Journal of Cardiovascular Pharmacology and Therapeutics | April 30, 2018 | Volume: 23 | Issue: 5 | Pages: 387-398

10.1177/1074248418769612 | PMID 29706106 Get It

Pazopanib is an approved treatment for renal cell carcinoma and a second-line treatment for nonadipocytic soft-tissue sarcoma. However, its clinical efficacy is limited by its cardiovascular side effects. Pazopanib and other vascular endothelial growth factor receptor tyrosine kinase inhibitors have been associated with the development of hypertension, QT interval prolongation, and other cardiovascular events; however, these mechanisms are largely unknown. Gaining a deeper understanding of these mechanisms is essential for the development of appropriate surveillance strategies and possible diagnostic biomarkers to allow us to monitor patients and modulate therapy prior to significant cardiac insult. This approach will be vital in keeping patients on these life-saving therapies and may be applicable to other tyrosine kinase inhibitors as well. In this review, we provide a comprehensive overview of the preclinical and clinical side effects of pazopanib with a focus on the mechanisms responsible for its toxicity to the cardiovascular system.
Frequency and Acceptability of Adverse Events After Anterior Cervical Discectomy and Fusion
Wilson, Jefferson R. , Schroeder, Gregory D. , Booth, Madison, Lucasti, Christopher , Fehlings, Michael G. , Nassr, Ahmad, Sciubba, Daniel M. , Ching, Alex, Smith, Justin S. , Shaffrey, Christopher I. , Singh, Kern , Darden, Bruce V., Daffner, Scott D. , Ludwig, Steven C. , Wang, Jeffrey , Lehman, Ronald A. , Hilibrand, Alan S. , Yoon, Tim , Grauer, Jonathan N. , Dailey, Andrew T. , Steinmetz, Michael P. , Ahmad, Nassr, Fehlings, Michael G , Radcliff, Kris E. , Vaccaro, Alexander R. , Arnold, Paul M. , Cheng, Ivan , Ghogawala, Zoher , Buchowski, Jacob M. , Brodke, Darrel Scott , Harrop, James Shields

Mayo Clinic

Clinical Spine Surgery: A Spine Publication | April 27, 2018 | Volume: 31 | Issue: 5 | Pages: E270-E277

10.1097/bsd.0000000000000645 | PMID 29708891 Get It

Purpose: Anterior cervical discectomy and fusion has a low but well-established profile of adverse events. The goal of this study was to gauge surgeon opinion regarding the frequency and acceptability of these events. Methods: A 2-page survey was distributed to attendees at the 2015 Cervical Spine Research Society (CSRS) meeting. Respondents were asked to categorize 18 anterior cervical discectomy and fusion–related adverse events as either: “common and acceptable,” “uncommon and acceptable,” “uncommon and sometimes acceptable,” or “uncommon and unacceptable.” Results were compiled to generate the relative frequency of these responses for each complication. Responses for each complication event were also compared between respondents based on practice location (US vs. non-US), primary specialty (orthopedics vs. neurosurgery) and years in practice. Results: Of 150 surveys distributed, 115 responses were received (76.7% response rate), with the majority of respondents found to be US-based (71.3%) orthopedic surgeons (82.6%). Wrong level surgery, esophageal injury, retained drain, and spinal cord injury were considered by most to be unacceptable and uncommon complications. Dysphagia and adjacent segment disease occurred most often, but were deemed acceptable complications. Although surgeon experience and primary specialty had little impact on responses, practice location was found to significantly influence responses for 12 of 18 complications, with non-US surgeons found to categorize events more toward the uncommon and unacceptable end of the spectrum as compared with US surgeons. Conclusions: These results serve to aid communication and transparency within the field of spine surgery, and will help to inform future quality improvement and best practice initiatives.